Search

Displaying results 4481 - 4490 of 5923 in total
  1. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  2. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  4. Drug

    Vemtoberant

    go.drugbank.com/drugs/DB21607
    Investigational

    Vemtoberant has a monoisotopic molecular weight of 619.2 Da.

  5. Drug

    Delocamten

    go.drugbank.com/drugs/DB21711
    Investigational

    Delocamten has a monoisotopic molecular weight of 377.16 Da.

  6. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no...

  7. Drug

    Tasurgratinib

    go.drugbank.com/drugs/DB21222
    Investigational

    Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.

  8. Drug

    Geraniol

    go.drugbank.com/drugs/DB14183
    Approved

    Due to its anticancer effects, geraniol has been found to be effective against a broad range of cancers including breast, lung, colon, prostate, pancreatic, skin, liver, kidney and oral cancers [A34262

  9. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS+7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN

  10. Drug

    Methoxyamine

    go.drugbank.com/drugs/DB06328
    Investigational